162 related articles for article (PubMed ID: 35775313)
41. Randomized Controlled Trial of Trastuzumab With or Without Chemotherapy for HER2-Positive Early Breast Cancer in Older Patients.
Sawaki M; Taira N; Uemura Y; Saito T; Baba S; Kobayashi K; Kawashima H; Tsuneizumi M; Sagawa N; Bando H; Takahashi M; Yamaguchi M; Takashima T; Nakayama T; Kashiwaba M; Mizuno T; Yamamoto Y; Iwata H; Kawahara T; Ohashi Y; Mukai H;
J Clin Oncol; 2020 Nov; 38(32):3743-3752. PubMed ID: 32936713
[TBL] [Abstract][Full Text] [Related]
42. Cost-effectiveness of pertuzumab combined with trastuzumab and docetaxel as a first-line treatment for HER-2 positive metastatic breast cancer.
Leung HWC; Chan ALF; Muo CH; Leung JH
Expert Rev Pharmacoecon Outcomes Res; 2018 Apr; 18(2):207-213. PubMed ID: 28965422
[TBL] [Abstract][Full Text] [Related]
43. Adjuvant Chemotherapy and Trastuzumab Is Safe and Effective in Older Women With Small, Node-Negative, HER2-Positive Early-Stage Breast Cancer.
Cadoo KA; Morris PG; Cowell EP; Patil S; Hudis CA; McArthur HL
Clin Breast Cancer; 2016 Dec; 16(6):487-493. PubMed ID: 27622751
[TBL] [Abstract][Full Text] [Related]
44. Human epidermal growth factor receptor 2 expression in early breast cancer patients: a Swiss cost-effectiveness analysis of different predictive assay strategies.
Blank PR; Schwenkglenks M; Moch H; Szucs TD
Breast Cancer Res Treat; 2010 Nov; 124(2):497-507. PubMed ID: 20364309
[TBL] [Abstract][Full Text] [Related]
45. Economic evaluation of margetuximab vs. trastuzumab for pretreated ERBB2-positive advanced breast cancer in the US and China.
Tang Z; Xu X; Gao J; Chen L; Zhu Q; Wang J; Yan X; Chen B; Zhu Y
Front Public Health; 2022; 10():942767. PubMed ID: 36159262
[TBL] [Abstract][Full Text] [Related]
46. Cost-effectiveness analysis of trastuzumab to treat HER2-positive advanced gastric cancer based on the randomised ToGA trial.
Shiroiwa T; Fukuda T; Shimozuma K
Br J Cancer; 2011 Oct; 105(9):1273-8. PubMed ID: 21959871
[TBL] [Abstract][Full Text] [Related]
47. Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial.
Harbeck N; Huang CS; Hurvitz S; Yeh DC; Shao Z; Im SA; Jung KH; Shen K; Ro J; Jassem J; Zhang Q; Im YH; Wojtukiewicz M; Sun Q; Chen SC; Goeldner RG; Uttenreuther-Fischer M; Xu B; Piccart-Gebhart M;
Lancet Oncol; 2016 Mar; 17(3):357-366. PubMed ID: 26822398
[TBL] [Abstract][Full Text] [Related]
48. An economic evaluation of trastuzumab as adjuvant treatment of early HER2-positive breast cancer patients in Colombia.
Buendía JA; Vallejos C; Pichón-Rivière A
Biomedica; 2013; 33(3):411-7. PubMed ID: 24652177
[TBL] [Abstract][Full Text] [Related]
49. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
50. Assessing the potential cost-effectiveness of retesting IHC0, IHC1+, or FISH-negative early stage breast cancer patients for HER2 status.
Garrison LP; Lalla D; Brammer M; Babigumira JB; Wang B; Perez EA
Cancer; 2013 Sep; 119(17):3113-22. PubMed ID: 23775560
[TBL] [Abstract][Full Text] [Related]
51. A global economic model to assess the cost-effectiveness of new treatments for advanced breast cancer in Canada.
Beauchemin C; Letarte N; Mathurin K; Yelle L; Lachaine J
J Med Econ; 2016 Jun; 19(6):619-29. PubMed ID: 26850287
[TBL] [Abstract][Full Text] [Related]
52. Cost-effectiveness analysis of neoadjuvant pertuzumab and trastuzumab therapy for locally advanced, inflammatory, or early HER2-positive breast cancer in Canada.
Attard CL; Pepper AN; Brown ST; Thompson MF; Thuresson PO; Yunger S; Dent S; Paterson AH; Wells GA
J Med Econ; 2015 Mar; 18(3):173-88. PubMed ID: 25347449
[TBL] [Abstract][Full Text] [Related]
53. Cost-effectiveness of pertuzumab and trastuzumab biosimilar combination therapy as initial treatment for HER2-positive metastatic breast cancer in Singapore.
Cheng LJ; Loke L; Lim EH; Pearce F; Aziz MIA; Ng K
Expert Rev Pharmacoecon Outcomes Res; 2021 Jun; 21(3):449-456. PubMed ID: 33595372
[TBL] [Abstract][Full Text] [Related]
54. Health-Related Quality of Life With Trastuzumab Monotherapy Versus Trastuzumab Plus Standard Chemotherapy as Adjuvant Therapy in Older Patients With HER2-Positive Breast Cancer.
Taira N; Sawaki M; Uemura Y; Saito T; Baba S; Kobayashi K; Kawashima H; Tsuneizumi M; Sagawa N; Bando H; Takahashi M; Yamaguchi M; Takashima T; Nakayama T; Kashiwaba M; Mizuno T; Yamamoto Y; Iwata H; Ohashi Y; Mukai H; Kawahara T;
J Clin Oncol; 2021 Aug; 39(22):2452-2462. PubMed ID: 33835842
[TBL] [Abstract][Full Text] [Related]
55. From Research to Policy Implementation: Trastuzumab in Early-Stage Breast Cancer Treatment in Thailand.
Kongsakon R; Lochid-Amnuay S; Kapol N; Pattanaprateep O
Value Health Reg Issues; 2019 May; 18():47-53. PubMed ID: 30428405
[TBL] [Abstract][Full Text] [Related]
56. Assessing the real-world cost-effectiveness of adjuvant trastuzumab in HER-2/neu positive breast cancer.
Hedden L; O'Reilly S; Lohrisch C; Chia S; Speers C; Kovacic L; Taylor S; Peacock S
Oncologist; 2012; 17(2):164-71. PubMed ID: 22302231
[TBL] [Abstract][Full Text] [Related]
57. Trastuzumab for the treatment of primary breast cancer in HER2-positive women: a single technology appraisal.
Ward S; Pilgrim H; Hind D
Health Technol Assess; 2009 Jun; 13 Suppl 1():1-6. PubMed ID: 19567207
[TBL] [Abstract][Full Text] [Related]
58. Trastuzumab Emtansine for Treating HER2-Positive, Unresectable, Locally Advanced or Metastatic Breast Cancer After Treatment with Trastuzumab and a Taxane: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Squires H; Stevenson M; Simpson E; Harvey R; Stevens J
Pharmacoeconomics; 2016 Jul; 34(7):673-80. PubMed ID: 26892972
[TBL] [Abstract][Full Text] [Related]
59. Trastuzumab in early stage breast cancer: a cost-effectiveness analysis for Belgium.
Neyt M; Huybrechts M; Hulstaert F; Vrijens F; Ramaekers D
Health Policy; 2008 Aug; 87(2):146-59. PubMed ID: 18164510
[TBL] [Abstract][Full Text] [Related]
60. [Cost-effectiveness of trastuzumab in the treatment of early stages breast cancer patients, in Portugal].
Macedo A; Monteiro I; Andrade S; Cirrincione A; Ray J
Acta Med Port; 2010; 23(3):475-82. PubMed ID: 20654267
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
